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fterload Reduction in
hronic Aortic Regurgitation
t Sure Seems Like a Good Idea*
homas M. Bashore, MD, FACC†
urham, North Carolina
“The beginning of knowledge is the discovery of something we do
not understand.”
Frank Herbert (1920 to 1986) (1)
n this issue of the Journal, Scognamigilio et al. (2) from
adua, Italy, follow up their prior observation on the value
f afterload reduction in patients with aortic insufficiency
AI) and normal left ventricular (LV) function (3) by
eporting on those that developed LV dysfunction before
urgery.
See page 1025
Their initial study revealed that AI patients pretreated
ith nifedipine (compared to digoxin) did much better after
ortic valve replacement (AVR). Concerns regarding short-
cting nifedipine, though, have resulted in mostly alterna-
ive afterload reducing agents being used. This has occurred
espite essentially no data on how much to use and whether
he practice should be continued postoperatively. This
trategy of afterload reduction is supported by the American
eart Association/American College of Cardiology Task
orce on the valvular disease and is incorporated into their
ecent guidelines (4).
In the authors’ current randomized trial, they observe
hat, while the nifedipine-pretreated group is similar to the
ontreated group in regard to LV end-diastolic volume
EDV), LV end-systolic volume (ESV), and ejection frac-
ion (EF) going into surgery, they are not after AVR. This
retreatment effect becomes even more evident at the 5-year
nd 10-year anniversaries after AVR (presumably despite no
urther treatment with nifedipine). The implication is that
ifedipine afterload reduction does something good that
ersists long after the AI is resolved, even in those with an
bnormal ventricle.
HE EFFECT OF AI ON
ENTRICULAR FUNCTION MEASUREMENTS
ortic insufficiency results in increased preload or diastolic
all stress (due to the volume overload) and increased
fterload or systolic stress (due to the ejection of blood into
*Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or theL
merican College of Cardiology.
From †Duke University Medical Center, Durham, North Carolina.he high-impedance aorta). Peripheral vascular tone, aortic
ompliance, viscoelasticity, blood inertia, and reflected
aves all contribute to the latter (5). Myocardial hypertro-
hy develops in response to systolic wall stress by the
aplace relationship (pressure radius/2 wall thickness).
n response to the increased diastolic stress, sarcomeres
eplicate end-to-end to handle the extra volume. This
ncreases systolic wall stress and results in further hypertro-
hy to return systolic stress back to normal. Because the
hamber is large relative to wall thickness, this process has
een termed “eccentric” hypertrophy. In the compensated
tate, contractile function remains preserved. Eventually,
hough, myocardial failure ensues via a series of complex
vents that include changes in the myocyte phenotype due
o re-expression of fetal genes, cellular apoptosis, alteration
n the expression or function of contractile proteins, changes
n the extracellular matrix, and abnormalities in cellular
nergetics (6).
Patients remain asymptomatic for long periods. Symp-
oms usually emerge when diastolic dysfunction occurs.
nfortunately, systolic dysfunction invariably precedes dia-
tolic dysfunction in chronic AI. Determining when systolic
ysfunction has occurred then becomes the key to following
hese patients. Because AI alters the loading conditions,
ommonly used measures, such as the EF, poorly reflect the
ontractile state. The simplest way to understand all this
linically is to examine the effect of AI on the pressure-
olume relationship and note what happens when contrac-
ility decreases. In Figure 1, the normal pressure-volume
elationship is represented by a box. The limits of the box
epresent the ESV and EDV; the width is the stroke
olume. The EF is simply the width of the “box” divided by
he EDV. Each beat of the heart is represented by this “box”
nd resides nestled between a line of “systolic contractility”
similar to Emax) and a line of “diastolic compliance.” At
ny level of contractility and compliance, the heart beats
errily away within these confines. The calculated EF
rovides only a surrogate for a better surrogate (Emax) that
s itself a surrogate for contractility in the intact heart.
Figure 2A schematically shows what happens in AI.
espite no change in the line of contractility, increased
fterload makes the “box” higher, the ESV greater, the box
idth more narrow, and the EF lower. Increased preload
akes the EDV greater, the width of the box (SV) larger,
nd the EF higher. Because the increased preload is a much
igger deal in AI than the afterload, the result is a relatively
ormal or slightly increased EF in most AI patients.
As contractility declines (Fig. 2B), the slope of the line of
contractility” drops resulting in the pressure-volume “box”
etting narrower (lower EF) and the ESV getting larger.
he most important measures to follow are, thus, the ESV
or dimensions) and the EF. This simple concept has been
sed over the years to help decide operability in AI and
emains valid to this day. It is now generally accepted that
V end-diastolic dimension of 65 mm and an EF of

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Editorial Comment April 5, 2005:1031–355% represents the compensated state, while end-systolic
imensions of 50 mm or an EF 50% represents decom-
ensation even in asymptomatic patients (4).
Earlier attempts at defining early LV systolic dysfunction
n AI patients addressed exercise reserve, usually with
adionuclide angiography. However, tachycardia reduces
iastolic time and the regurgitant volume per beat, making
nterpretation of exercise EF difficult at best. Inadequate
ypertrophy may also be reflected by an increase in end-
ystolic wall stress (ESS), but measures of this have been
et with little enthusiasm. Combining exercise EF and
tress measurements, Borer et al. (7) examined the decrement
n the change of EF per unit of exercise-induced increment
n ESS and found this measure superior to LVEF or
entricular sizes in picking out those likely to develop heart
ailure. Unfortunately this valiant effort has not caught on
linically either. So we are pretty much stuck with using the
esting EF and ESV measures. Fortunately, as a recent
ditorial noted, when contractility indexes are not measured,
he LV end-systolic dimension still emerges as the best
rognostic indicator (8).
While contractility had already declined in patients reported
igure 1. The mathematics of the ejection fraction. The normal pressure-
olume loop is represented as a box that is confined by a line of contractility
nd a line of diastolic compliance. The ejection fraction (EF) is simply the
idth of the box (stroke volume [SV]) divided by the left ventricular
nd-diastolic volume (LVEDV). EDV  end-diastolic volume; ESV 
nd-systolic volume. AC  aortic closure; AO  aortic opening; MC 
itral closure; MO  mitral opening.y Scognamigilio et al. (2), afterload reduction did prolong the pime from disease recognition to AVR. Other measured
aseline factors (including a comorbidity index) were similar
etween the two groups except for age. Women are thought to
ave a similar operative risk after AVR, but a reduced 10-year
urvival. In this report, there are an equal number of women in
ach group. The authors also report an extremely low surgical
ortality in these low EF patients (1%). This is no small feat
nd flies in the face of other studies with an operative mortality
f about 14% in this situation (9).
OW DOES NIFEDIPINE MAKE ALL THIS BETTER?
ow pretreatment with nifedipine improves the outlook for
ears after surgical intervention is unclear. The presumption
s that this is somehow due to the consequences of afterload
eduction. While the systolic blood pressures were elevated,
here was no difference between the groups. Chronic after-
oad reduction with hydralazine, angiotensin-converting
nzyme inhibitors, or other calcium channel blockers have
een shown to reduce LV sizes and improve the EF, though
hort-term studies have not shown that hypertrophy is
revented (10).
In particular, why did nifedipine have a protective effect
ong after AVR? One can hallucinate a variety of thoughts,
ut none have much validity. Does the afterload reduction
igure 2. The effect of aortic insufficiency (AI). (A) Compares AI to the
ormal. In AI the pressure-volume “box” is wider due to the volume
verload and taller due to the afterload increase. These increase end-
ystolic (ESV) and end-diastolic (EDV) volumes. The overall ejection
raction (EF) is generally elevated. In (B), as the slope of the line of
ontractility drops, the ESV has to rise, and the EF has to fall.revent irreversible changes in myocyte geometry or in the
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April 5, 2005:1031–3 Editorial Commentxtracellular matrix (11) that recovers after AVR? Or could
here be something unique about the use of a calcium
locker? For instance, it is known that myocardial blood
ow is altered in AI and improved after aortic valve
eplacement (12); might nifedipine simply be having a
avorable effect on myocardial blood flow preoperatively that
llows for even better perfusion and recovery of the myo-
ardium postoperatively?
Though it seems unlikely, are the negative inotropic
ffects of nifedipine simply being removed when the drug is
topped after surgery? It has been demonstrated that chronic
lockage of the myocardial calcium channels with nifedipine
esults in their upregulation (13).
It is known that sudden death from cardiac arrhythmias
ay be initiated by delayed afterdepolarizations that result
rom an aberrant sarcoplasmic reticulum calcium leak (14);
ight the improved survival related to the use of nifedipine
e somehow related to improved calcium homeostasis
ithin the myocardial cell itself? To date, there is little to
upport such as role, as nifedipine apparently has no action
n the ryanodine sarcoplasmic reticulum receptor (15). In a
ery different setting, diltiazem has been reported to prevent
ardiomyopathy in a mouse model of hypertrophic cardio-
yopathy (16).
So why does this seem to work? In such a clinical
bservational study, the answers to these and other ques-
ions beg for an explanation. The results, however, are
ntriguing and important, and the authors are to be con-
ratulated for pulling off a long-term study of this nature.
iven the fact that the cardiology community has accepted
he notion of afterload reduction in this setting, it is unlikely
hat a similar study will ever be funded using other
fterload-reducing agents. That is a real shame, because we
nderstand so little about what is going on. Their data do
dd a measure of comfort to our current practice, even if we
emain clueless as to why the effect persists for such an
xtended time after AVR. Afterload reduction in AI sure
eems like a good idea.
eprint requests and correspondence: Dr. Thomas M. Bashore,
uke University Medical Center, Box 3012, Durham, North
arolina 27710. E-mail: thomas.bashore@duke.edu.EFERENCES
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